Gapping up
Select oil/gas related names showing strength:
- RDS.A +1.7%, BP +1.2%, CVX +0.6%, SLB +0.6%, USO +0.5%, XOM +0.5%
Other news:
- ENOB +142.2% (announces that the FDA has accepted a Pre-IND request for a potential functional cure or treatment of HIV)
- ITOS +51.3% (Iteos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448)
- ETTX +23.5% (completed the Second Closing and issued 6,268,975 shares of Common Stock and 6,268,975 Warrants to Innoviva (INVA) for an aggregate gross purchase price of approximately $12.5 million)
- BTX +11.8% ( intends to acquire Novellus Therapeutics)
- AVXL +9.7% (reported that ANAVEX2-73 (blarcamesine) and ANAVEX3-71 (AF710B) are featured in a new peer-reviewed publication)
- NVAX +9.6% (reports its COVID-19 Vaccine demonstrates 90% overall efficacy)
- FLGC +8.5% (signed a Letter of Intent to acquire 100% of the outstanding equity interests of Switzerland based Koch & Gsell and its wholly-owned hemp brand, Heimat)
- ESTE +6.1% (acquired working interests in assets it operates located in southern Gonzales County, Texas from four separate sellers)
- SRNE +6% (announces that UK's regulatory agency, MHRA, has cleared Sorrento's COVI-DROPS product candidate for a Phase 2 efficacy trial)
- CANO +5.3% (acquires University Health Care for $600 mln; raised FY21 guidance)
- NKTX +5.3% (elects CEO Paul Hastings as Chair of the Board for the 2021-2022 term)
- FMTX +4.6% (appoints John E. Bishop, Ph.D., to the leadership team as senior vice president and chief technology officer)
- HGEN +2% (submits Lenzilumab Marketing Authorization to UK's MHRA)
- SWAV +1.5% (announces CMS approval for Transitional Pass-Through payment for C2 Coronary IVL device)
- GBT +1.3% (receives Promising Innovative Medicine in UK for Voxelotor)
Analyst comments:
- NVGS +4.1% (upgraded to Outperform from In-line at Evercore ISI)
- AUTL +3.6% (upgraded to Buy from Hold at Jefferies)
- CMG +2.4% (upgraded to Strong Buy from Outperform at Raymond James)
- ENLC +1.8% (upgraded to Outperform from Mkt Perform at Raymond James)
- CQP +1.5% (upgraded to Buy from Neutral at Goldman)
- CRSP +1% (upgraded to Neutral from Sell at Citigroup)